請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44020完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 于明暉 | |
| dc.contributor.author | Chiao-Ni Wen | en |
| dc.contributor.author | 溫巧尼 | zh_TW |
| dc.date.accessioned | 2021-06-15T02:36:34Z | - |
| dc.date.available | 2016-08-16 | |
| dc.date.copyright | 2011-10-03 | |
| dc.date.issued | 2011 | |
| dc.date.submitted | 2011-08-16 | |
| dc.identifier.citation | 1.Liaw, Y.-F., and Chu, C.-M. 2009. Hepatitis B virus infection. The Lancet 373:582-592.
2.Yu, M.-W., and Chen, C.-J. 1994. Hepatitis B and C viruses in the development of hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 17:71-91. 3.Chen, C.-J., Yu, M.-W., and Liaw, Y.-F. 1997. Epidemiological characteristics and risk factors of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 12:S294-S308. 4.Perz, J.F., Armstrong, G.L., Farrington, L.A., Hutin, Y.J.F., and Bell, B.P. 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatology 45:529-538. 5.Giovanna, F., Bortolotti, F., and Francesco, D. 2008. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. Journal of Hepatology 48:335-352. 6.Chang, M.-H. 2008. Natural history and clinical management of chronic hepatitis B virus infection in children. Hepatology International 2:28-36. 7.Stevens, C.E., Beasley, R.P., Tsui, J., and Lee, W.-C. 1975. Vertical Transmission of Hepatitis B Antigen in Taiwan. New England Journal of Medicine 292:771-774. 8.Yu, M.-W., Chang, H.-C., Liaw, Y.-F., Lin, S.-M., Lee, S.-D., Liu, C.-J., Chen, P.-J., Hsiao, T.-J., Lee, P.-H., and Chen, C.-J. 2000. Familial Risk of Hepatocellular Carcinoma Among Chronic Hepatitis B Carriers and Their Relatives. Journal of the National Cancer Institute 92:1159-1164. 9.Lu, S.-N., Su, W.-W., Yang, S.-S., Chang, T.-T., Cheng, K.-S., Wu, J.-C., Lin, H.H., Wu, S.-S., Lee, C.-M., Changchien, C.-S., et al. 2006. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. International Journal of Cancer 119:1946-1952. 10.Cha, C., and DeMatteo, R.P. 2005. Molecular mechanisms in hepatocellular carcinoma development. Best Practice & Research Clinical Gastroenterology 19:25-37. 11.Dunsford, H.A., Sell, S., and Chisari, F.V. 1990. Hepatocarcinogenesis Due to Chronic Liver Cell Injury in Hepatitis B Virus Transgenic Mice. Cancer Research 50:3400-3407. 12.Huang, S.N., and Chisari, F.V. 1995. Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology (Baltimore, Md.) 21:620-626. 13.Chisari, F.V., Filippi, P., Buras, J., McLachlan, A., Popper, H., Pinkert, C.A., Palmiter, R.D., and Brinster, R.L. 1987. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proceedings of the National Academy of Sciences 84:6909-6913. 14.Chisari, F.V., Klopchin, K., Moriyama, T., Pasquinelli, C., Dunsford, H.A., Sell, S., Pinkert, C.A., Brinster, R.L., and Palmiter, R.D. 1989. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59:1145-1156. 15.Yang, H.-I., Lu, S.-N., Liaw, Y.-F., You, S.-L., Sun, C.-A., Wang, L.-Y., Hsiao, C.K., Chen, P.-J., Chen, D.-S., and Chen, C.-J. 2002. Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma. New England Journal of Medicine 347:168-174. 16.Yu, M.W., Yeh, S.H., Chen, P.J., Liaw, Y.F., Lin, C.L., Liu, C.J., Shih, W.L., Kao, J.H., Chen, D.S., and Chen, C.J. 2005. Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men. JNCI Journal of the National Cancer Institute 97:265-272. 17.Wu, C.F., Yu, M.W., Lin, C.L., Liu, C.J., Shih, W.L., Tsai, K.S., and Chen, C.J. 2007. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 29:106-112. 18.Sung, F.Y., Jung, C.M., Wu, C.F., Lin, C.L., Liu, C.J., Liaw, Y.F., Tsai, K.S., and Yu, M.W. 2009. Hepatitis B Virus Core Variants Modify Natural Course of Viral Infection and Hepatocellular Carcinoma Progression. Gastroenterology 137:1687-1697. 19.Huang, H.H., Shih, W.L., Li, Y.H., Wu, C.F., Chen, P.J., Lin, C.L., Liu, C.J., Liaw, Y.F., Lin, S.M., Lee, S.D., et al. 2010. Hepatitis B viraemia: its heritability and association with common genetic variation in the interferon signalling pathway. Gut 60:99-107. 20.Zakian, V.A. 1995. Telomeres: Beginning to Understand the End. Science 270:1601-1607. 21.Hunt, S.C., Chen, W., Gardner, J.P., Kimura, M., Srinivasan, S.R., Eckfeldt, J.H., Berenson, G.S., and Aviv, A. 2008. Leukocyte telomeres are longer in African Americans than in whites: the National Heart, Lung, and Blood Institute Family Heart Study and the Bogalusa Heart Study. Aging Cell 7:451-458. 22.Takubo, K., Izumiyama-Shimomura, N., Honma, N., Sawabe, M., Arai, T., Kato, M., Oshimura, M., and Nakamura, K.-I. 2002. Telomere lengths are characteristic in each human individual. Experimental Gerontology 37:523-531. 23.Passos, J.F., Saretzki, G., and von Zglinicki, T. 2007. DNA damage in telomeres and mitochondria during cellular senescence: is there a connection? Nucleic Acids Research 35:7505-7513. 24.Chimenti, C., Kajstura, J., Torella, D., Urbanek, K., Heleniak, H., Colussi, C., Di Meglio, F., Nadal-Ginard, B., Frustaci, A., Leri, A., et al. 2003. Senescence and Death of Primitive Cells and Myocytes Lead to Premature Cardiac Aging and Heart Failure. Circulation Research 93:604-613. 25.Lee, M., Martin, H., Firpo, M.A., and Demerath, E.W. 2011. Inverse association between adiposity and telomere length: The fels longitudinal study. American Journal of Human Biology 23:100-106. 26.Babizhayev, M.A., and Yegorov, Y.E. 2011. Smoking and health: association between telomere length and factors impacting on human disease, quality of life and life span in a large population-based cohort under the effect of smoking duration. Fundamental & Clinical Pharmacology 25:425-442. 27.Effros, R.B. Telomere/telomerase dynamics within the human immune system: Effect of chronic infection and stress. Experimental Gerontology 46:135-140. 28.Shen, M., Cawthon, R., Rothman, N., Weinstein, S.J., Virtamo, J., Hosgood, H.D., 3rd, Hu, W., Lim, U., Albanes, D., and Lan, Q. 2011. A prospective study of telomere length measured by monochrome multiplex quantitative PCR and risk of lung cancer. Lung Cancer 73:133-137. 29.Lan, Q., Cawthon, R., Shen, M., Weinstein, S.J., Virtamo, J., Lim, U., Hosgood, H.D., 3rd, Albanes, D., and Rothman, N. 2009. A prospective study of telomere length measured by monochrome multiplex quantitative PCR and risk of non-Hodgkin lymphoma. Clin Cancer Res 15:7429-7433. 30.Roos, G., Kröber, A., Grabowski, P., Kienle, D., Bühler, A., Döhner, H., Rosenquist, R., and Stilgenbauer, S. 2008. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood 111:2246-2252. 31.Willeit, P., Willeit, J., Mayr, A., Weger, S., Oberhollenzer, F., Brandstätter, A., Kronenberg, F., and Kiechl, S. 2010. Telomere Length and Risk of Incident Cancer and Cancer Mortality. JAMA: The Journal of the American Medical Association 304:69-75. 32.Svenson, U., Ljungberg, B., and Roos, G. 2009. Telomere Length in Peripheral Blood Predicts Survival in Clear Cell Renal Cell Carcinoma. Cancer Research 69:2896-2901. 33.Wentzensen, I.M., Mirabello, L., Pfeiffer, R.M., and Savage, S.A. 2011. The Association of Telomere Length and Cancer: a Meta-analysis. Cancer Epidemiology Biomarkers & Prevention 20:1238-1250. 34.Rudolph, K.L., Chang, S., Lee, H.-W., Blasco, M., Gottlieb, G.J., Greider, C., and DePinho, R.A. 1999. Longevity, Stress Response, and Cancer in Aging Telomerase-Deficient Mice. Cell 96:701-712. 35.Artandi, S.E., Chang, S., Lee, S.-L., Alson, S., Gottlieb, G.J., Chin, L., and DePinho, R.A. 2000. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 406:641-645. 36.Campbell, P.J., Yachida, S., Mudie, L.J., Stephens, P.J., Pleasance, E.D., Stebbings, L.A., Morsberger, L.A., Latimer, C., McLaren, S., Lin, M.-L., et al. 2010. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467:1109-1113. 37.Murnane, J.P. 2010. Telomere Loss as a Mechanism for Chromosome Instability in Human Cancer. Cancer Research 70:4255-4259. 38.Rafnar, T., Sulem, P., Stacey, S.N., Geller, F., Gudmundsson, J., Sigurdsson, A., Jakobsdottir, M., Helgadottir, H., Thorlacius, S., Aben, K.K.H., et al. 2009. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 41:221-227. 39.Farazi, P.A., Glickman, J., Jiang, S., Yu, A., Rudolph, K.L., and DePinho, R.A. 2003. Differential Impact of Telomere Dysfunction on Initiation and Progression of Hepatocellular Carcinoma. Cancer Research 63:5021-5027. 40.Plentz, R.R., Caselitz, M., Bleck, J.S., Gebel, M., Flemming, P., Kubicka, S., Manns, M.P., and Rudolph, K.L. 2004. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology 40:80-86. 41.Miura, N., Horikawa, I., Nishimoto, A., Ohmura, H., Ito, H., Hirohashi, S., Shay, J.W., and Oshimura, M. 1997. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genetics and Cytogenetics 93:56-62. 42.Plentz, R.R., Schlegelberger, B., Flemming, P., Gebel, M., Kreipe, H., Manns, M.P., Rudolph, K.L., and Wilkens, L. 2005. Telomere shortening correlates with increasing aneuploidy of chromosome 8 in human hepatocellular carcinoma. Hepatology 42:522-526. 43.Kim, H., Oh, B.-K., Roncalli, M., Park, C., Yoon, S.-M., Yoo, J.E., and Park, Y.N. 2009. Large liver cell change in hepatitis B virus–related liver cirrhosis. Hepatology 50:752-762. 44.Liu, J., Yang, Y., Zhang, H., Zhao, S., Liu, H., Ge, N., Yang, H., Xing, J.-L., and Chen, Z. 2011. Longer leukocyte telomere length predicts increased risk of hepatitis b virus-related hepatocellular carcinoma. Cancer:DOI: 10.1002/cncr.26015. 45.Effros, R.B. 2011. Telomere/telomerase dynamics within the human immune system: Effect of chronic infection and stress. Experimental Gerontology 46:135-140. 46.Cawthon, R.M. 2009. Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Research 37:e21. 47.Cawthon, R.M. 2002. Telomere measurement by quantitative PCR. Nucleic Acids Research 30:e47. 48.Artandi, S.E., and DePinho, R.A. 2010. Telomeres and telomerase in cancer. Carcinogenesis 31:9-18. 49.Song, Z., Von Figura, G., Liu, Y., Kraus, J.M., Torrice, C., Dillon, P., Rudolph-Watabe, M., Ju, Z., Kestler, H.A., Sanoff, H., et al. 2010. Lifestyle impacts on the aging-associated expression of biomarkers of DNA damage and telomere dysfunction in human blood. Aging Cell 9:607-615. 50.Shammas, M.A. 2011. Telomeres, lifestyle, cancer, and aging. Current Opinion in Clinical Nutrition & Metabolic Care 14:28-34 10.1097/MCO.1090b1013e32834121b32834121. 51.Young, N.S. 2010. Telomere Biology and Telomere Diseases: Implications for Practice and Research. Hematology 2010:30-35. 52.Bellon, M., and Nicot, C. 2008. Regulation of Telomerase and Telomeres: Human Tumor Viruses Take Control. Journal of the National Cancer Institute 100:98-108. 53.Tahara, H., Nakanishi, T., Kitamoto, M., Nakashio, R., Shay, J.W., Tahara, E., Kajiyama, G., and Ide, T. 1995. Telomerase Activity in Human Liver Tissues: Comparison between Chronic Liver Disease and Hepatocellular Carcinomas. Cancer Research 55:2734-2736. 54.Satra, M., Dalekos, G.N., Kollia, P., Vamvakopoulos, N., and Tsezou, A. 2005. Telomerase reverse transcriptase mRNA expression in peripheral lymphocytes of patients with chronic HBV and HCV infections. Journal of Viral Hepatitis 12:488-493. 55.Lee, J.-E., Oh, B.-K., Choi, J., and Park, Y.N. 2008. Telomeric 3′ overhangs in chronic HBV-related hepatitis and hepatocellular carcinoma. International Journal of Cancer 123:264-272. 56.Zhang, X., Dong, N., Zhang, H., You, J., Wang, H., and Ye, L. 2005. Effects of hepatitis B virus X protein on human telomerase reverse transcriptase expression and activity in hepatoma cells. Journal of Laboratory and Clinical Medicine 145:98-104. 57.Kew, M.C. 2011. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 26:144-152. 58.d'Adda di Fagagna, F. 2008. Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer 8:512-522. 59.Campisi, J. 2001. Cellular senescence as a tumor-suppressor mechanism. Trends in Cell Biology 11:S27-S31. 60.Wright, W.E., and Shay, J.W. The two-stage mechanism controlling cellular senescence and immortalization. Experimental Gerontology 27:383-389. 61.Chin, K., de Solorzano, C.O., Knowles, D., Jones, A., Chou, W., Rodriguez, E.G., Kuo, W.-L., Ljung, B.-M., Chew, K., Myambo, K., et al. 2004. In situ analyses of genome instability in breast cancer. Nat Genet 36:984-988. 62.Mooi, W.J., and Peeper, D.S. 2006. Oncogene-Induced Cell Senescence — Halting on the Road to Cancer. New England Journal of Medicine 355:1037-1046. 63.Oh, B.-K., Kim, H., Park, Y.N., Yoo, J.E., Choi, J., Kim, K.-S., Lee, J.J., and Park, C. 2007. High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis. Lab Invest 88:144-152. 64.Kitada, T., Seki, S., Kawakita, N., Kuroki, T., and Monna, T. 1995. Telomere Shortening in Chronic Liver Diseases. Biochemical and Biophysical Research Communications 211:33-39. 65.Yokota, T., Suda, T., Igarashi, M., Kuroiwa, T., Waguri, N., Kawai, H., Mita, Y., and Aoyagi, Y. 2003. Telomere length variation and maintenance in hepatocarcinogenesis. Cancer 98:110-118. 66.Sekoguchi, S., Nakajima, T., Moriguchi, M., Jo, M., Nishikawa, T., Katagishi, T., Kimura, H., Minami, M., Itoh, Y., Kagawa, K., et al. 2007. Role of cell-cycle turnover and oxidative stress in telomere shortening and cellular senescence in patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology 22:182-190. 67.van de Berg, P.J.E.J., Griffiths, S.J., Yong, S.-L., Macaulay, R., Bemelman, F.J., Jackson, S., Henson, S.M., ten Berge, I.J.M., Akbar, A.N., and van Lier, R.A.W. 2010. Cytomegalovirus Infection Reduces Telomere Length of the Circulating T Cell Pool. The Journal of Immunology 184:3417-3423. 68.Aubert, G., and Lansdorp, P.M. 2008. Telomeres and Aging. Physiological Reviews 88:557-579. 69.Wolkowitz, O.M., Mellon, S.H., Epel, E.S., Lin, J., Dhabhar, F.S., Su, Y., Reus, V.I., Rosser, R., Burke, H.M., Kupferman, E., et al. 2011. Leukocyte Telomere Length in Major Depression: Correlations with Chronicity, Inflammation and Oxidative Stress - Preliminary Findings. PLoS ONE 6:e17837. 70.Santen, R.J., Willis, P.W., III, and Fajans, S.S. 1972. Atherosclerosis in Diabetes Mellitus: Correlations With Serum Lipid Levels, Adiposity, and Serum Insulin Level. Arch Intern Med 130:833-843. 71.2007. Critical Roles of Insulin-Induced Senescence in Diabetic Vasculopathy. Vascular Disease Prevention 4:194-200. 72.Chao, L.T., Wu, C.F., Sung, F.Y., Lin, C.L., Liu, C.J., Huang, C.J., Tsai, K.S., and Yu, M.W. 2011. Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. Carcinogenesis 32:876-881. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44020 | - |
| dc.description.abstract | 背景：端粒長度過短與慢性病毒感染有關，亦會增加各種癌症的風險，而本研究的目的：欲探討在控制病毒量後白血球端粒長度與肝細胞癌之間的相關性。
材料方法：本研究之研究對象為1121名B型肝炎帶原者，其中119名為肝細胞癌於追蹤期間的新發病例。研究對象均從研究世代中隨機抽取。此研究世代為1989年至1992年間在公保中心接受健檢的B型肝炎男性帶原者，年齡於三十歲以上，共計2903人加入，追蹤至2006年。白血球端粒長度是以SYBR-Green Q-PCR方法進行測量。分析方法則以非條件式羅吉斯迴歸控制相關干擾因子後，評估白血球端粒長度與病毒因子和肝細胞癌之間的相關性。 結果：控制年齡、吸菸與喝酒習慣後，均和白血球端粒長度第三三分位組相比，端粒長度第一三分位組與第二三分位和肝細胞癌之OR分別為1.84 (95% 信賴區間=1.14-2.98) 和0.93 (95%信賴區間=0.54-1.58)。HBV基因型為白血球端粒長度與肝細胞癌之間的修飾因子，在調整干擾因子後，以HBV基因型分層，HBV基因型非C型與HBV基因型C型分別來看，均和白血球端粒長度第三三分位組相比，端粒長度第一三分位組其肝細胞癌之OR分別為4.58 (95% 信賴區間=2.14-9.79) 和0.68 (95%信賴區間=0.30-1.57)。然而，本研究沒有發現白血球端粒長度與HBV長期病毒量之間的相關性。 結論：在慢性B型肝炎帶原者中，白血球端粒長度過短為肝細胞癌的危險因子。 | zh_TW |
| dc.description.abstract | Background & Aims: Shorten leukocyte telomere length has been associated with chronic viral infection other than hepatitis B virus (HBV) as well as increased risks for cancers at various anatomic sites. The purposes of this study are to evaluate the role of leukocyte telomere length in control of hepatitis B viral load, and in subsequent development of hepatocellular carcinoma (HCC).
Materials and Methods: Study subjects included a total of 1121 male HBV carriers (of whom 119 HCC cases were ascertained during follow-up) ages≥30 years sampled from a cohort (1989-1992) of 2903 male government employees chronically infected with HBV who have been followed until 2006. Relative telomere length in leukocytes was assessed using a quantitative SYBR-Green real time polymerase chain reaction method. Unconditional logistic regression was used to determine the association between relative leukocyte telomere length and viral factors and HCC after adjustment for potential confounders. Results: After adjustment for age at recruitment,cigarette smoking, and alcohol consumption, the odds ratios (ORs) of HCC in decreasing tertiles of relative telomere length were 1.00, 0.93 (95% confidence interval [CI]=0.54-1.58), and 1.84 (95% CI= 1.14-2.98), respectively. This association was significantly modified by HBV genotype (P for interaction<0.0001), with the adjusted OR of HCC being larger in carriers of HBV non-C genotype (shortest vs. longest tertile: OR=4.58, 95% CI=2.14-9.79) than in carriers of HBV genotype C (shortest vs. longest tertile: OR=0.68, 95% CI=0.30-1.57). However, there was no convincing evidence of any association between relative leukocyte telomere length and control of HBV viral load. Conclusions: Among male HBV carriers, shorter leukocyte telomere length is an independent risk factor for the development of HCC. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T02:36:34Z (GMT). No. of bitstreams: 1 ntu-100-R98842009-1.pdf: 800033 bytes, checksum: 6a0dc07a12aa659b643084744814abf6 (MD5) Previous issue date: 2011 | en |
| dc.description.tableofcontents | 致謝 i
中文摘要 ii Abstract iii Background 1 Materials and Methods 6 Study cohort 6 Case-cohort study 6 Telomere length measurement 7 Assay of viral factors 8 Statistical analysis 8 Results 10 Baseline characteristics of HCC cases and non-HCC subjects 10 Relative telomere length and demographics 10 Relative telomere length and metabolic factors 11 Relative telomere length and hepatitis B viral factors 11 Relative telomere length and clinical outcomes 11 Relative telomere length and HCC in selected subgroups 12 Discussion 13 References 18 | |
| dc.language.iso | en | |
| dc.subject | 世代研究 | zh_TW |
| dc.subject | 白血球端粒長度 | zh_TW |
| dc.subject | B型肝炎病毒 | zh_TW |
| dc.subject | B型肝炎病毒血症 | zh_TW |
| dc.subject | 肝細胞癌 | zh_TW |
| dc.subject | hepatitis B virus | en |
| dc.subject | cohort | en |
| dc.subject | hepatocellular carcinoma | en |
| dc.subject | HBV viremia | en |
| dc.subject | leukocyte telomere length | en |
| dc.title | 白血球端粒長度與慢性B型肝炎病毒血症和肝細胞癌風險之前瞻性研究 | zh_TW |
| dc.title | Prospective Study of Leukocyte Telomere Length with Hepatitis B Viremia Levels and Hepatocellular Carcinoma Risk | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 99-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 楊雅倩(Ya-Chien Yang),蔡孟勳,林志陵 | |
| dc.subject.keyword | 白血球端粒長度,B型肝炎病毒,B型肝炎病毒血症,肝細胞癌,世代研究, | zh_TW |
| dc.subject.keyword | leukocyte telomere length,hepatitis B virus,HBV viremia,hepatocellular carcinoma,cohort, | en |
| dc.relation.page | 29 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2011-08-17 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-100-1.pdf 未授權公開取用 | 781.28 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。